Skip to content

PYXS - Pyxis Oncology, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchP

Pyxis Oncology Inc

PYXS · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

P

PYXSPyxis Oncology Inc

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $5.55
52-wk low: $1.03
Prev close: $3.54
Mkt cap: $281.1M
Beta: 1.32
P/S: 25.5x

Smart money

8 funds hold a position.

Real smart money

Funds holding this stock

8 holders

Combined position$9.7M

MW
Marshall Wace
Q2 2026 13F
$2.5M
position
JS
Jim Simons
Q2 2026 13F

Earnings

Reported May 14, 2026

Earnings came in 5.7% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $281M

Valuation

P/S25.47
P/B21.80

Quality

Operating margin-813.0%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: PYXS
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $281.08M
Beta: 1.32

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

P/B

21.8x

Profit margin

+0.0%

Op margin

-813.0%

ROE

-179.1%

$2.3M

position

MI

Millennium

Israel Englander · Q2 2026 13F

$701K

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for PYXS

No recent insider trade
No recent Congress trade
No recent market-voice mention

Earnings per share

-$0.37-5.7%

-$0.35 expected

Next report

What the street expects next

EPS expected

-$0.28

-$0.36 to -$0.22

Revenue expected

$0.00

9 analysts

Last 30 days

1up2down

Analysts cutting estimates

-179.1%

ROA-62.9%

Growth

Beta1.32